Skip to content
Visionary Ventures
Venture capital fund investing life sciences focusing in ophthalmology medical devices and pharmaceuticals.
Visionary VenturesVisionary Ventures
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN
Fund Menu
Search
  • HOME
  • OPHTHALMOLOGY FUND
  • Visionary KOLs
  • TEAM
    • Investment Committee
    • Fund Management
  • PORTFOLIO
  • NEWS
  • CONTACT
  •  INVESTOR LOGIN

Daily Archives: March 15, 2022

Orasis Pharmaceuticals Concludes Phase 3 Clinical Trials for Presbyopia Candidate

News, OrasisBy Garrett HamontreeMarch 15, 2022

Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an innovative pharmaceutical solution for the treatment of presbyopia symptoms, today announced the initiation of NEAR-1 and NEAR-2 Phase 3 clinical studies in the U.S., evaluating its novel eye drop candidate designed to improve near vision for people with presbyopia.

  • Home
  • Ophthalmology
  • Team
    • Investment Committee
    • Visionary KOLs
    • Fund Management
  • Portfolio
  • News
  • Contact
  • Investor Portal
Footer Menu

© 2019 Visionary Ventures. All Rights Reserved.

Go to Top